TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Echinaforce COVID-19 Shedding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 12 - 75 years.~* Written informed consent.~* Ability and willingness to give oropharyngeal swab samples.~* Positive pre-screening SARS-CoV-2 RT-PCR virus test with an above threshold viral load as per qPCR (Cq ≤ 27).~Exclusion Criteria:~* ≥76 years~* \<12 years.~* Participation in another clinical study in the past 30 days or planned during study conduct.~* Severe COVID19~* Intake of antimicrobial, antiviral, immune suppressive substances.~* Surgical intervention in the 3 months prior enrolment~* Known diabetes mellitus.~* Known and medicated atopy or asthma.~* Cystic Fibrosis, bronchopulmonary dysfunction, COPD.~* Known immune system disorders and degenerative disorders (autoimmune disorders, AIDS, leukemia, lymphoma, myeloma).~* Known metabolic or resorption disorders.~* Known liver or kidney illnesses (chronic hepatitis, liver cirrhosis, chronic kidney insufficiency).~* Serious health conditions (limited general condition, auto-immune diseases, tumorous diseases, neurological disorders or serious Covid-19)~* Known allergies to plants of the compositae family (e.g. chamomile or dandelion) or to one of the compounds in the investigational product~* Known pregnancy.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- treatment group 1: Echinaforce Forte (EFF) Tablets (chewed) (Type: ACTIVE_COMPARATOR): 1st arm (EFF group): Slowly sucking 1 Echinaforce Forte tablet (1 tablet: 1'200mg EF) until dissolution Dose 1. Another 2 X 1 EF Forte tablets (total of 2 tablets: 2'400 mg EF) is taken one-by-one Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Forte tablets.
- treatment gorup 2: Echinaforce Chewable (EFC) Tablets (chewed) (Type: ACTIVE_COMPARATOR): 2nd arm (EFC group): Slowly sucking 1 x 3 Echinaforce Chewable tablets (total 3 tablets: 1'200mg EF) until dissolution Dose 1. Another dose of 2 x 2 \& 1 x 3 EF Chewable tablets (total 7 tablets: 2'800mg EF) are slowly sucked Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Chewable tablets.
- treatment group 3: Echinaforce Tincture (EFT, gargling) (Type: ACTIVE_COMPARATOR): 3rd arm (EFT group): Gargling of 2 x 19 drops of Echinaforce tincture (1'200 mg EF) is diluted in 2 x35 mL water Dose 1. Another dose of 3 x 30 drops of Echinaforce tincture (2'800 mg EF) diluted in 3 x35 mL water for 15 sec each Dose 2, gargled for 15 sec and swallowed after swab sampling, which is repeated after gargling of the second dose of EF Tincture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with dysphagia following head and neck cancer treatment~* Patients without endoscopic or radiological evidence suggestive of tumor recurrence~* Patients refractory to endoscopic treatment~Exclusion Criteria:~* Endoscopic or radiological signs suggestive of tumor recurrence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Endoscopic injection of Mitomycin C (Type: OTHER): Endoscopy injection of Mitomycin C will be perform to the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients with head and neck cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Childhood Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute lymphoblastic leukemia, excluding known mature B-cell ALL~* \< 18 years of age~* Patients who are leukopheresed or exchanged are eligible for study only after completion of the pheresis or exchange transfusion~* Absence of a t(8,14) (q24; q32), t (8,22), t(2,8)~* Total bilirubin \< 1.4mg/dl~Exclusion Criteria:~* Known HIV positive~* Prior steroid therapy within 30 days of diagnosis~* Septic shock~* Ongoing intracranial hemorrhage~* Clinical evidence of CNS or lung leukostasis

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute or Early HIV-1 infection~* HIV-1 RNA \> or equal to 500 copies/mL~* Acceptable safety lab results (specified in protocol)~* Negative pregnancy test for females~* Willingness to use contraception (for females of reproductive potential~Exclusion Criteria:~* Prior receipt of investigational HIV-1 vaccine~* Use of immunomodulators other than systemic steroids within 30 days before entry~* Serious medical or psychiatric illness that would interfere with study participation~* Active drug or alcohol use that would interfere with study participation~* Allergy/hypersensitivity to raltegravir~* Pre- or Post-exposure prophylaxis for the exposure that led to HIV-1 acquisition~* Pregnancy or breastfeeding~* History of malignancy (other than localized squamous cell or basal cell cancer of the skin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir + 3-drug anti-HIV therapy (Type: EXPERIMENTAL): None
- 3-drug anti-HIV therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are required to have histologically or pathologically confirmed metastatic gastric or esophageal adenocarcinoma.~* Patients must demonstrate relapse or progression after at least one prior line of chemotherapy for metastatic disease.~* Patients must have measurable disease by CT scan or MRI~* Absolute neutrophil count ≥ 1,500/uL, platelet ≥ 100,000/uL and Hgb \> 8.0 g/dl.~* Total bilirubin ≤ upper institutional limit of normal (ULN), and AST or ALT ≤ 3x ULN; if liver metastases then AST or ALT \< 5x ULN~* Peripheral neuropathy must be ≤ Grade 1~* Creatinine \< 2 x ULN~* ECOG performance status 0 to 2~* Minimum life expectancy of 12 weeks.~* Age older than 18 years.~* Voluntary, signed written informed consent.~* Women of childbearing potential must have a negative pregnancy test Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.~Exclusion Criteria:~* History of severe hypersensitivity reaction to Cabazitaxel or other drugs formulated with polysorbate 80.~* Patients with known, untreated brain metastasis~* Any uncontrolled severe, intercurrent illness.~* Women who are breast-feeding.~* Patients who have undergone major surgery, chemotherapy, or radiotherapy within the last 3 weeks.~* Patients on concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- real drug (Type: EXPERIMENTAL): patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Beetroot Juice to Protect Against Postoperative Ileus (POI) Following Colorectal Surgery: a Pilot Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~• All patients undergoing colonic or upper rectum laparoscopic surgery.~Exclusion Criteria:~* Pregnancy or breast feeding~* Psychiatric pathology capable of affecting comprehension and judgment faculty~* History of metastatic disease~* History of prior abdominal bowel surgery~* Abdominal radiation treatment~* Chronic constipation (defined as two or fewer bowel movements per week)~* Gut motility influencing agents (e.g. tricyclic antidepressants, chronic use of laxatives)~* Frequent use of mouthwash, as this affects the enterosalivary circulation of nitrate~* Current use of broad-spectrum antibiotics, which will affect the oral flora and likely affect the nitrate reductase activity~* More than one bowel anastomosis during this surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Beetroot juice (Type: ACTIVE_COMPARATOR): None
- Control group 1 (Type: PLACEBO_COMPARATOR): None
- Control group 2 (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients need to be in a normal sinus rhythm preoperatively.~2. Participants undergoing planned lobectomy and 60 years of age or older or participants undergoing planned pneumonectomy and 18 years of age or older.~3. Planned procedure is 5 days after the start of taking study drugs.~4. Signed written informed consent~5. Women of childbearing potential must have a negative pregnancy test (A woman of childbearing potential is a women who has not been naturally postmenopausal for at least 12 consecutive months or who has not undergone previous surgical sterilization)~6. Adequate liver function evidenced by; aspartate aminotransferase (AST or SGOT) \</= 2.5 \* Upper Limits of Normal (ULN), and alanine aminotransferase (ALT or SGPT) \</= 2.5 \* ULN~Exclusion Criteria:~1. Any history of supraventricular arrhythmia for which the patient is taking medications.~2. Current use of antiarrhythmic medications other than beta-receptor antagonists, calcium-channel antagonists, or digitalis.~3. Use of any supplemental n-3 fatty acids during the previous three months.~4. Use of any statin therapy during the previous three months.~5. Patients known to have a history of recent drug or alcohol abuse.~6. Known allergy to seafood~7. Current use of Gemfibrozil and Fenofibrate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): 1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
- Fish Oil Supplement (Type: EXPERIMENTAL): 3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
- Placebo (Type: PLACEBO_COMPARATOR): 4 capsules orally every morning and 3 every evening for 5 days pre-surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patients With Tracheostomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years, meeting the diagnosis of severe Traumatic Brain Injury;~* score of Glasgow Coma Scale\<8;~* presence of no contraindication for enteral nutrition;~* with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications;~* informed consent form was obtained from the patient\&#39;s family members, indicating their full understanding of the study and agreement to participate.~Exclusion Criteria:~* unable to cooperate in completing treatment and assessment due to personal reasons or other disorders;~* complicated with other intracranial lesions, such as stroke;~* with severe consciousness disorders caused by other diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- the observation group (Type: EXPERIMENTAL): Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
- the control group (Type: ACTIVE_COMPARATOR): Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old~* Evidence of typical anatomical pattern to the left ventriculography (total akinesia of the mid-apical segments with hypercontractility basal segments) associated with the presence of criteria for the diagnosis of Takotsubo syndrome (Table 1)~* signing of informed consent~Exclusion Criteria:~* allergy to adenosine~* known and documented diagnosis of asthma~* pre-existing ischemic heart disease~* presence of arrhythmic complication (AV block grade II type 2 and third degree)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adenosine (Type: EXPERIMENTAL): Patients in this arm will receive systemic infusion of adenosine at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
- Saline solution (Type: PLACEBO_COMPARATOR): Patients in this arm will receive systemic infusion of saline solution at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CD4 Count \>50~* Viral load 200-75,000 on two most recent measures~* More than 16 weeks on standard dose Kaletra (LPV/r)~* May be initial PI regimen or prior PI usage~* Up to 50-fold resistance to LPV/r~Exclusion Criteria:~* Age \< 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Laser Treatment for Fresh Surgical Scars and Mature Scars

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fitzpatrick Skin Type I-VI and either a fresh surgical scar (with sutures still present \[or dissolving sutures within 7 days of surgery for facial scars or within 14 days of surgery for scars on the trunk or extremities) of at least 2cm in length or an erythematous and/or hypertrophic scar of at least 2cm in length and of greater than or equal to 18 months in duration~* Scar is easily divisible into two equal segments for the purpose of the study, or is bilateral in nature (e.g., inframammary)~Exclusion Criteria:~* Pregnant, lactating, or is planning to become pregnant~* history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis~* any skin pathology/condition that could interfere with evaluation or requires the use of interfering topical systemic therapy~* coagulation disorder or currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)~* any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in the study~* currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days~* unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function~* unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits~* Isotretinoin therapy within 6 months~* need to be exposed to artificial tanning devices or excessive sunlight during the trial~* prior treatment with parenteral gold therapy~* does not agree to refrain from other laser treatment, (micro)dermabrasion or topical scar treatment creams for the duration of the study~* Diabetes Type 1 or 2~* Lupus, scleroderma or similar immune system disorder~* underlying silicone or other non-absorbable filler in the area of the scar~* phenol chemical peel or dermabrasion to the area of the scar within 3 months~* Fitzpatrick Skin Type IV, V or VI with a known sensitivity to hydroquinone or is unwilling or unable to comply with physician/manufacturer instructions for the use of this ingredient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Fresh surgical scars (Type: EXPERIMENTAL): Treatment of scars
- Mature scars (Type: EXPERIMENTAL): Treatment of scars

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Esophageal Dysmotility - Prospective Study Evaluating Methods for Esophageal Dilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old~* Dysphagia to liquids and/or solids~* Diagnosis of esophageal dysmotility~* Normal endoscopic exam~Exclusion Criteria:~* Diagnosis of achalasia~* Defined strictures or webs~* Vulnerable populations:~* Adults unable to consent (Individuals who are not yet adults (infants, children, teenagers), Pregnant women, Prisoners)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dilation by Balloon (Type: ACTIVE_COMPARATOR): Esophageal dilation by balloon device.
- Dilation by Semi-rigid Savary (Type: ACTIVE_COMPARATOR): Esophageal dilation by semi-rigid savary device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues